Globe Life (GL) shares have been moving as investors focus on an upcoming second quarter earnings announcement and expectations for a double digit profit increase, set against generally bullish analyst sentiment.
See our latest analysis for Globe Life.
Globe Life's recent 30 day share price return of 19.49% and 30.39% year to date gain, alongside a 1 year total shareholder return of 49.85%, indicate that momentum has been building as investors focus on the upcoming earnings update and the recent refinancing of its credit and term loan facilities.
If the recent move in Globe Life has you considering where else momentum and growth stories may be developing, this could be a good moment to check out 20 top founder-led companies
With Globe Life now trading close to recent analyst targets yet carrying an intrinsic value estimate that implies a large gap, the key question is simple: is the stock still undervalued, or is the market already pricing in future growth?
Most Popular Narrative: 4.9% Overvalued
Globe Life's most followed narrative puts fair value at $172.10, slightly below the last close of $180.49, which sets up a subtle valuation tension.
The planned establishment of a Bermuda reinsurance affiliate is expected to significantly increase parent company free cash flow and financial flexibility by 2027 and beyond, providing greater capacity for share repurchases and/or strategic investments, positively impacting earnings per share.
Want to see what sits underneath that reinsurance move and buyback capacity? The narrative relies on specific revenue, margin and earnings assumptions that are anything but casual.
Result: Fair Value of $172.10 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Globe Life's reliance on agent driven distribution and the overhang from DOJ and SEC investigations could disrupt growth assumptions and sentiment if conditions turn less favorable.
Find out about the key risks to this Globe Life narrative.
Another View: Globe Life Through a Cash Flow Lens
While the most popular Globe Life narrative points to a fair value of $172.10 and labels the stock as 4.9% overvalued versus the recent $180.49 share price, a separate look using our DCF model presents a different perspective.
On this approach, Globe Life at $180.49 is described as trading at a large discount to an estimated future cash flow value of $360.56, which implies it may screen as materially undervalued rather than slightly expensive. Two models pointing in opposite directions raise an important question for you as an investor: which set of assumptions appears more realistic for Globe Life's future cash generation and risk profile?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Globe Life for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 43 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
The mix of optimism and caution around Globe Life is clear. Consider reviewing the data, weighing both sides, and forming your own view quickly using the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Globe Life?
If Globe Life has sharpened your focus on valuation and risk, do not stop here. Use the Simply Wall Street Screener to surface other focused opportunities.
- Zero in on quality at a discount by checking companies highlighted in the 43 high quality undervalued stocks
- Prioritise resilience by scanning stocks with the 75 resilient stocks with low risk scores
- Get ahead of the crowd by reviewing under followed opportunities through the screener containing 18 high quality undiscovered gems
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com